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Abstract
Cardiovascular disease (CVD) is a worldwide health problem with growing up rates of mortality and morbidity. Many risk
factors, including high blood pressure, cigarette smoking, diabetes, obesity, and dyslipidemia are responsible for CVD. CVD can
be prevented by some simple and cost-effective steps such as smoking cessation, normalizing body weight, regular physical
activity, and dietary changes, including decreasing saturated fats, increasing the intake of vegetables and fruits, and reducing
sugar intake. In the last decades, growing up number of studies were performed to explain the possible function of non-nutrient
substances from the diet which might prevent CVD. One of these natural compounds is quercetin which is widely present in
vegetables, tea, fruits and wine. Many in vitro, in vivo and clinical studies have indicated the cardioprotective functions of
quercetin. They can be explained by quercetin’s reducing blood pressure, antioxidant potential and some other activities. This
review evaluates the experimental and clinical studies that have studied the effect of quercetin in CVD and summarizes the
molecular mechanisms of action as well as clinical effects of quercetin in CVD.
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CVD Cardiovascular disease
WHO World Health Organization
ROS Reactive oxygen species
IL-1 Interleukin-1
IFN-γ Interferon-γ
TNF-α Tumor necrosis factor-α
TNF-β Tumor necrosis factor-β
MCP-1 monocyte chemoattractant protein-1
IL-8 Interleukin-8
VCAM-1 Vascular cell adhesion molecule-1
PDGF Platelet-derived growth factor
TGF-β Transforming growth factor-β








Nox Nitrite and nitrate





Atherosclerotic cardiovascular disease (CVD) is the principal
cause of mortality and morbidity worldwide [1, 2]. Over 80%
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The World Health Organization states that about 75% of CVD
mortality may be prevented by preventing strategies [4]. During
the past decades, different advances in the prevention and med-
ication of CVD have decreased death rates of CVD by 50% [5].
Simple and cost-effective steps such as smoking cessation,
achieving healthy body weight, regular physical activity, and
dietary changes, including decreasing the consumption of satu-
rated fats, increasing the intake of vegetables and fruits, and
reducing sugar intake may prevent CVD development [6].
Several factors are important in atherosclerotic CVD pathogen-
esis. Atherosclerosis is a heterogeneous disease in which risk
factors such as dyslipidemia, arterial high blood pressure,
smoking, diabetes, chronic inflammation, and obesity play the
key roles [7, 8].
Recently, patient’s demand for non-pharmacological
options became a reality. Therefore, it is necessary for
physicians to be aquainted with the safety and effective-
ness of these options [9, 10]. In the last decades, more
and more studies have been published concerning the
function of non-nutrient substances in the diet which
might have some effects on preventing CVD [11].
Some of these natural compounds are flavonoids which
exist in fruits and vegetables as well as some beverages
and supplementations. Quercetin is a well-known flavo-
noid which is one of the most famous dietary antioxi-
dants. It is widely present in vegetables, tea, fruits and
wine [12]. The name is derived from quercetum (oak
forest), after Quercus [13]. Chemical structure of quer-
cetin is an unconjugated aglycone that does not have a
carbohydrate moiety [13]. A quercetin glycoside is con-
structed by binding a glycosyl group (mostly glucose,
rhamnose, or rutinose) as a substitutive for one of the
OH groups [13]. Taken strictly, the term quercetin
should be applied to the aglycone only [13, 14]. Both
types of molecules are easily bioavailable but the gly-
coside form causes better bioavailability than its agly-
cone type [13–15]. All derivatives of quercetin are
absorbed in the upper segment of small intestine [16,
17]. In the plasma, quercetin is transported to the liver
by albumin [18, 19]. In the liver, it is transformed to its
metabolites, including isorhamnetin, tamarixetin and
kaempferol. The half-lives of quercetin and its metabo-
lites are 11 to 28 h suggesting considerable plasma con-
centrations of quercetin after its consumption [20]. A
large number of studies have been carried out to eluci-
date the mechanism of action and toxicological proper-
ties of quercetin. Evidence from experimental and clin-
ical studies has suggested the cardiovascular protective
effects of quercetin. It has been documented that quer-
cetin might have effects on CVD by reducing blood
pressure, by its antioxidant, interference with the renin-
angiotensin-aldosterone system, and/or improving vascu-
lar function in an endothelium-dependent [11].
Pathogenesis of Atherosclerosis and CVD:
Mechanisms
The development of the levels of atherosclerosis from an early
fatty streak lesion to a highly hazardous rupture-prone plaque
is due to the many molecular and cellular events at each level.
One of the important processes involved in atherogenesis is
endothelial dysfunction and oxidative stress which leads to
reactive oxygen species (ROS) generation, including superox-
ide anion, lipid peroxides, hydrogen peroxide and
peroxynitrite. Antioxidants in diet and enzymes like glutathi-
one peroxidase inactivate ROS and therefore low concentra-
tions of these enzymes act as pro-atherosclerotic factors [21].
High amounts of oxidative stress which is mediated by several
factors, including abnormal salt control of kidney, elevated
levels of angiotensin II, and smoking also occur in hyperten-
sion [22].
In the subendothelial space, elevated levels of ROS cause
the oxidation of LDL particles which is one of the first steps
towards atherosclerosis [23]. Monocytes enter the
subendothelial space and get transformed into macrophages
oxidized LDL particles rich in cholesterol and transform into
foam cells. This process is accompanied by a low-grade
chronic inflammation. Many cytokines, including
interleukin-1 (IL-1), interferon-γ (IFN-γ), tumor necrosis
factor-β (TNF-β) and angiotensin II as well as several
chemokine’s containing monocyte chemoattractant protein-1
(MCP-1), interleukin-8 (IL-8), CXC cytokines and eotaxin
elevate adhesion molecules expression such as vascular cell
adhesion molecule-1 (VCAM-1), P- and E-selectin and there-
by attract inflammatory and immune cells, including mono-
cytes, T and B lymphocytes, leukocytes and mast cells from
the blood flow [24].
Leukocytes attached to the adhesion molecules enter the
subendothelial space. Growth factors such as platelet-derived
growth factor (PDGF) and transforming growth factor-β
(TGF-β) induce smooth muscle cell (SMC) to migrate from
intima to media, to proliferate and secrete collagen leading to
fatty-fibrous lesion or atherosclerotic plaque. These lesions
develop by remodeling and neo-vascularisation which can
cause CVD events. The stable plaques have a thick fibrous
cap with a smaller lipid core and have low concentrations of
inflammatory cells and cytokines. Lipid-lowering therapy can
conquer such plaques [25]. The unstable plaques have a thin-
ner fibrous cap, more lipids in the core and a higher content of
inflammatory cells and are prone to extreme inflammation.
Lipid-lowering therapy can transform such plaques into stable
lesions [25]. Also several pro-apoptotic cytokines including
TNF-β, matrixmetalloproteinases, which digest collagenmol-
ecules, and IFN-γ, which suppress collagen secretion, are pro-
duced by inflammatory cells. The accumulation of cholesterol
from LDL particles induces apoptosis in macrophages which
is prone to develop atherosclerosis by cholesterol transfer to
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endoplasmic reticulum membranes and signaling cholesterol-
induced apoptosis [26]. Rupture of the plaques occurs often
without any symptoms. In such situation, the thrombus which
is formed on the place of rupture is absorbed into the plaques.
PDGF and TGF-β stimulate the growth of the plaques which
together induce SMC proliferation and the formation of a
dense collagen matrix thus thickening the cap of the plaque.
On the other hand, new micro-vessels within the plaque are
prone to break which results in intra-plaque hemorrhage con-
tributing to plaque instability [27].
Risk Factors of CVD and their Molecular
Mechanisms
Multiple studies suggested that hypertension leads to athero-
sclerosis by several synergistic processes which involve oxi-
dative stress and inflammation in the arterial wall [28, 29].
Many environmental and genetic factors may modulate the
effect of hypertension on CVD. It has been confirmed that
blood pressure lowering strategies are effective in delaying
the formation of atherosclerosis lesions and CVD [30].
Smoking is another factor which is the major cause of CVD
[31]. Contents of cigarette such as nicotine and carbon mon-
oxide impair the structure of the arteries; stimulate developing
of the atherosclerotic plaques, and elevate concentrations of
circulating non-esterified fatty acids which increase inflam-
matory response. Smoking generates ROS leading to oxida-
tive stress and increased levels of oxidized LDL that promotes
atherosclerosis. Advanced CVD is often more found in pa-
tients with diabetes in comparison with patients without dia-
betes and diabetes is accepted as an important risk factor for
CVD [32]. Multiple mechanisms in diabetes are responsible
for this such as oxidative stress, abnormal vessels reactivity,
renal dysfunction, which all participate in atherogenesis and
increase the risk of CVD [33]. Another important risk factor
CVD is obesity. Obesity is one of the most principal compo-
nents of the metabolic syndrome which also promotes athero-
sclerosis [34]. Multiple molecules activated in obesity influ-
ence oxidative stress and inflammation and therefore CVD.
IL-6which is produced in adipocytes is increased by increased
number of adipocytes. Increased concentrations of IL-6 in-
duce C-reactive protein (CRP) production in the liver which
decreases the levels of nitric oxide (NO) leading to vasocon-
striction, increased vascular resistance and finally endothelial
dysfunction [35]. Dyslipidemia, and particularly elevated
LDL-C levels, has also a key role in CVD. One of the primary
causes of damage to the artery wall is elevated LDL-C in the
blood [36]. Higher levels of LDL-C lead to adhesion of leu-
kocytes to the endothelium and the production of foam cells.
Foods rich in saturated fats and trans-fatty acids and abnormal
LDL receptors are the most often causes of hypercholesterol-
emia and therefore of atherosclerosis [37]. There are several
markers for CVD, including CRP, CD40 ligand, and troponin.
CRP is one of the principal markers of inflammation and
atherosclerosis which is independent of other markers [38].
It is formed in the liver by induction of cytokines such as
IL-6. CRP is present in lesions where binds to oxidized LDL
and acts as a chemo-attractant by increasing the expression of
adhesion molecules. During myocardial injury, the cytoplasm
of cardiomyocytes release myofilament troponin. Acute coro-
nary syndrome especially microinfarction can be recognized
by elevated cardiac troponin [39]. Soluble CD40 ligand is
another predictive marker of acute coronary syndromes. The
expression of soluble CD40 is found in leukocytes, smooth
muscle cells, endothelial cells and activated platelets.
Increased levels of soluble CD40 ligand shows the activation
of platelet and thereby elevated risk of cardiovascular events
[40, 41].
Quercetin and CVD
Antioxidant Effects of Quercetin in CVD
As already mentioned, oxidative stress is one of the main
processes in atherogenesis and CDV. Quercetin has the most
potent antioxidant properties compared with curcumin.
Presence of the hydroxyl (-OH) replacements and the
catechol-type B-ring in the structure of quercetin provides its
potent antioxidant features [42, 43]. A large number of studies
have suggested that quercetin is able to reduce oxidative inju-
ry in several tissues including brain, liver, aorta, kidney, and
cardiac muscle tissue [44]. Quercetin increases the cellular
antioxidant function via the Nrf2 pathway [45]. Quercetin
can also enhance the activity of antioxidant enzymes such as
superoxide dismutase (SOD) and catalase (CAT). Quercetin
has anti-diabetic effects as well as protects tissues such as
heart to oxidative injury induced by diabetes [46]. Hertog
et al. [47] observed reduced both total and LDL-C levels when
plasma levels of quercetin are elevated. Another study showed
that consumption of quercetin-rich foods decreased the mor-
tality related to coronary heart disease [48]. An experimental
study reported that pretreatment with quercetin decreased the
serum creatine kinase activity, lactate dehydrogenase, heart
mitochondrial lipid peroxidation products and increased mito-
chondrial antioxidants. Moreover, quercetin improves activi-
ties of the enzymes involved in tricarboxylic acid cycle and
respiratory chain in rats with myocardial infarction (MI) [49].
Chiş et al. [50] analyzed the effect of quercetin on the cardiac
hypoxia-induced oxidative stress biomarkers, including
malondialdehyde (MDA), protein carbonyl (PC) content, ni-
trite and nitrate (NOx) generation, inducible nitric oxide syn-
thase (iNOS) expression and antioxidant enzymes, including
SOD, and CAT in rats exposed to intermittent hypobaric hyp-
oxia. The results showed that in heart tissue of these rats
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MDA, PC, NOx, and iNOS expression decreased and the
activity of SOD and CAT increased as a result of quercetin
administration. This study indicated that increased hypoxia-
induced oxidative stress in heart tissue could be ameliorated
by quercetin. Another study suggested a cardioprotective ef-
fect of quercetin in rats with cadmium induced oxidative
cardiotoxicity and dyslipidemia in rats by increasing several
antioxidant enzymes including SOD, CAT, and gluthation
peroxidase [51].
Quercetin reduced cardiac diastolic dysfunction and cardi-
ac cholesterol accumulation in diabetic rats with hypercholes-
terolemia. It also decreased lipid peroxidation and PC content
and prevented alterations in peroxisome proliferator-activated
receptor gamma expression, decreased cardiac oxidative stress
via increasing the glutathione (GSH)/oxidized glutathione
(GSSG) ratio, the nuclear translocation of Nrf2 and the activ-
ity of antioxidant enzymes [52]. An experimental study eval-
uated the effects of quercetin on trauma-induced secondary
cardiac damage. Quercetin pretreatment potentially enhanced
post-traumatic cardiomyocyte apoptosis and cardiac dysfunc-
tion. Additionally, quercetin caused increased cell viability
and decreased TNF-α levels, and it reduced ROS and Ca2+
in myoblastic cells. Thus, quercetin may reverse post-
traumatic cardiac dysfunction by decreasing oxidative stress,
inflammation and apoptosis [53]. Oyagbemi et al. [54] report-
ed that quercetin in rats with hypertension decreased blood
pressure by improving antioxidant defense system. In rat
models, hypertension and oxidative stress were induced by
deoxycorticosterone acetate-salt. In these rats quercetin treat-
ment improved diastolic blood pressure and cardiac hypertro-
phy as well as antioxidant defense system, restored GSH con-
centrations in liver and heart. Thus, this study indicated the
anti-hypertensive and antioxidant roles of quercetin in a rat
model of hypertension [55] (Table 1).
Anti-Inflammatory Effects of Quercetin in CVD
Inflammatory response is a complex biological mechanism
which involves microvesels, molecular mediators and im-
mune cells stimulated by pathogens, irritants, damaged cells,
etc. [56]. Inflammation can clear up injured necrotic cells and
trigger the repair of damaged tissues. One of the most signif-
icant properties of quercetin is its modulatory effect on inflam-
mation. Quercetin can suppress inflammatory enzymes in-
cluding cyclooxygenase and lipooxygenase as well as pro-
inflammatory mediators [57, 58]. Pro-inflammatory cytokines
which are produced in stressful situations promote inflamma-
tion [59]. Asmentioned above, inflammation is a key player in
CVD.
Lu et al. [60] reported that quercetin decreased atheroscle-
rotic plaques in atherosclerotic mice. It was shown that quer-
cetin may reduce inflammatory process via suppressing endo-
thelial leukocyte adhesion and NF-kB signaling pathway in
endothelial cells and reduce the inflammatory response in ath-
erosclerotic rats and that it can inhibit atherosclerotic plaque
development [61]. Another study examined the influence of
quercetin on mice with lipopolysaccharide-induced cardiac
abnormalities. Quercetin had cardiovascular protective effect
by inhibiting the pro-inflammatory cytokines such as TNF-α
and IL-1β and suppressing IκB kinase phosphorylation [62].
Quercetin supplementation suppressed the nuclear transloca-
tion of NF-kB and cytokines release induced by ox-LDL
in vitro. Quercetin also decreased the gene expression of
TNF-α and toll-like receptors (TLRs) in atherosclerotic rats
suggesting that quercetin could be a promising agent in pre-
vention and medication of atherosclerosis by preventing in-
flammation [63]. Ma et al. [64] evaluated the effect of
isoquercetin on a rat model of acute MI. They observed that
isoquercetin improved MI size, creatine kinase, and the activ-
ity of lactic dehydrogenase. Moreover, quercetin suppressed
inflammation, oxidative stress and apoptosis of heart cells.
Quercetin also elevated endothelial NOS, decreased iNOS
and inhibited TLR4 NF-kB signaling pathway. This study
indicated the protective role of quercetin against acute myo-
cardial infarction by its anti-inflammatory and anti-apoptosis
properties. In another recent study, quercetin decreased lipid
peroxidation and reduced the expression of VCAM-1 and E-
selectin. Quercetin also inhibited atherosclerosis by reducing
inflammatory response [65]. In diabetic rats quercetin admin-
istration led to reduced blood pressure, reduced serum con-
centrations of TNF-α and CRP and inhibited aortic NF-kB.
The authors of this study suggested that quercetin could be an
effective candidate to prevent vascular disorders of diabetes
by its inhibitory effects on inflammation, particularly NF-kB
signaling [66] (Table 1).
Metabolic Effects of Quercetin in CVD (Clinical
Studies)
Quercetin due to anti-hypertensive, anti-atherosclerotic, anti-
platelet activity, and lipid-lowering effects has positive effects
on CVD. Consumption of the extract of red grape polyphenol
which is rich in quercetin causes an elevation of flow-
mediated dilation of main arteries indicating an improvement
in endothelial function [67]. Already a relatively old study
indicated that LDL oxidation is lower in people who take
quercetin and an alcohol-free red wine extract, containing
quercetin [68]. Quercetin also inhibits accumulation of fat in
human fat cells and initiates apoptosis in these cells [69, 70].
In other studies quercetin also inhibited glucose uptake from
the blood, the production of fat cells, and increased necrosis of
fat cells [71, 72].
In a randomized double-blinded placebo-controlled cross-
over clinical trial 70 overweight-to-obese patients with pre-
hypertension were selected to receive quercetin 162 mg per
day or placebo. The findings indicated that quercetin could
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reduce ambulatory blood pressure suggesting the
cardioprotective role of quercetin [73]. Pfeuffer et al. [74]
assessed the influence of quercetin on atherosclerosis risk fac-
tors, biomarkers of oxidative stress and inflammation in
healthy subjects with different APOE genotypes. These au-
thors reported that quercetin significantly reduced postprandi-
al systolic blood pressure without any changes on endothelial
function. Quercetin consumption also significantly decreased
postprandial triglycerides levels and increased HDL-
cholesterol levels when compared with placebo group.
Quercetin moderately elevated TNF-α levels as well. The au-
thors suggested that quercetin supplementation may improve
some CVD risk factors. The effects of quercetin on hyperten-
sion, lipid metabolism, markers of inflammation and oxidative
stress were analyzed in overweight or obese patients with
metabolic syndrome. Quercetin supplementation reduced se-
rum levels of HDL-cholesterol whereas total cholesterol, tri-
glycerides, LDL/HDL-cholesterol and triglycerides/HDL-
cholesterol ratios were not changed. On the other hand, quer-
cetin potentially reduced plasma levels of ox-LDL, while
TNF-α and CRP were not altered in comparison to those in
placebo group. Despite disappointing results concerning
lipids, this study showed that there might be some possible
beneficial effects of quercetin concerning CVD [75]. In an-
other study, drinking quercetin rich onion juice could signifi-
cantly suppressed cholesterol and elevate total antioxidant ca-
pacity levels [76].
Hubbard et al. [77] measured platelets isolated from sub-
jects who ingested quercetin-4’-O-beta-D-glucoside supple-
ment to analyze cell signaling and aggregation stimulated by
Table 1 Experimental studies of quercetin in CVD
Doses Problem Model Findings Ref
30 mg/kg Hypoxia In vivo Decreased MDA, PC, NOx and iNOS, increased
activity of SOD, CAT
[50]
50 mg/kg Oxidative cardiotoxicity
and dyslipidemia
In vivo Increased SOD, CAT, decreased lipid peroxidation
and PC content
[51]
0.5% w/w Diabetic myocardiopathy In vivo Decreased cardiac diastolic dysfunction, cardiac
cholesterol accumulation, and cardiac oxidative
stress, increased GSH/GSSH ratio, nuclear








apoptosis and cardiac dysfunction
Increased viability, decreased TNF-α, ROS
and Ca2+
[53]
50 and 100 mg/kg Hypertension In vivo Decreased blood pressure, improved antioxidant
defense system
[54]
10 mg/kg Hypertension In vivo Ameliorate diastolic blood pressure and cardiac
hypertrophy, improved antioxidant defense
system
[55]
50 and 100 mg/kg Atherosclerosis In vivo
In vitro
Decreased atherosclerotic plaque size






Decreased COX, MPO, CRP and IL-6
Decreased VCAM-1, ICAM-1, MCP-1 and
nuclear translocation of NF-kB p65 subunit
[61]
25 mg /kg LPS-induced cardiac abnormalities In vivo Decreased TNF-α and IL-1β, inhibited
activation of I-kB phosphorylation
[62]
50 mg/kg Atherosclerosis In vivo
In vitro
Decreased expression of TNF-α and TLRs
Inhibited nuclear translocation of NF-kB
[63]
– Acute mayocardial infarction In vivo Improved myocardial infarct size, creatine kinase,
and activity of LDH, decreased inflammation,
oxidative stress and apoptosis, increased
endothelial NOS, decreased iNOS, inhibited
TLR4 NF-kB signaling pathway
[64]
0.1%, w/w Atherosclerosis In vivo Decreased lipid peroxidation, expression of
VCAM-1 and E-selectin
[65]
50 mg/kg Diabetic myocardiopathy In vivo Decreased blood pressure, serum levels of TNF-α
and CRP, inhibited aortic NF-kB
[66]
CVD cardiovascular disease, COX cyclooxygenase, MPO myeloperoxidase, ROS reactive oxygen species, IFN-γ interferon-γ, TNF-α tumor necrosis
factor-α, MCP-1 monocyte chemoattractant protein-1, IL-1 interleukin-1, VCAM-1 vascular cell adhesion molecule-1, TGF-β transforming growth
factor-β, CRP C-reactive protein, NO nitric oxide, SOD superoxide dismutase, CAT catalase,MDA malondialdehyde, PC protein carbonyl, Nox nitrite
and nitrate, iNOS inducible nitric oxide synthase, LDH lactate dehydrogenase, NOS nitric oxide synthase, GSH glutathione, TLRs toll-like receptors
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collagen. The results indicated that quercetin inhibits platelet
cell signaling and thrombus formation. The effect of quercetin
on human hypertension was evaluated by Edwards et al. [78].
Nineteen subjects with pre-hypertension and 22 subjects with
stage 1 hypertension were receiving 730 mg quercetin or pla-
cebo daily for 28 days. After quercetin treatment, blood pres-
sure of pre-hypertensive subjects was not changed while the
blood pressure of stage 1 hypertensive subjects was reduced.
Another study also confirmed the blood pressure lowering
effect of quercetin. This study reported that quercetin de-
creased blood pressure via a mechanism which is not depen-
dent on angiotensin-converting enzyme, endothelin-1 or NO
(Table 2).
Conclusions
Nowadays, CVD is a worldwide health controversy with a
high rate of mortality and morbidity. Several risk factors con-
taining high blood pressure, smoking, diabetes, obesity, and
dyslipidemia are involved. Each of these factors can promote
several mechanisms and pathways by which atherosclerosis
and atherosclerotic CVD can develop. The main molecular
processes involved in CVD are including oxidative stress,
inflammation, apoptosis and endothelial dysfunction.
Quercetin as a natural compound has been considered to be
effective in the prevention and treatment of CVD (Fig. 1). In
the last two decades, several in vitro, in vivo and clinical trials
have been conducted in order to try to explain the mechanisms
of action of quercetin in CVD. The results have confirmed
some possible antiatherosclerotic effects of quercetin.
However, the details ofmolecular mechanisms bywhich quer-
cetin might achieve such effects have not yet been completely
clarified. Some authors have suggested that this is because of
its antioxidant, anti-inflammatory, and anti-apoptotic activi-
ties, protective effect on NO, anti-aggregation effect, blood
pressure lowering effects, and beneficial effects on endothelial
dysfunction. It could be concluded that quercetin seems to be
a promising therapeutic agent in preventing CVD are needed,
particularly those clinical with CVD outcomes. This is partic-
ularly important since there is no proof so far that quercetin
might prevent CVD morbidity and mortality.
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Table 2 Clinical trials of quercetin in CVD
Form of quercetin Doses Subjects Findings Ref
Quercetin 162 mg/d Pre-hypertension/
overweight-to-obese
Decreased ambulatory blood pressure [73]
Quercetin 150 mg/d Men with different APOE
isoforms
Decreased postprandial
systolic blood pressure, decreased postprandial
TAC, increased HDL-cholesterol, increased
TNF-α
[74]
Quercetin 150 mg/d Overweight or obese subjects
with metabolic syndrome
Decreased serum HDL-cholesterol, decreased
ox-LDL
[75]
quercetin-4’-O-beta-D-glucoside 150 or 300 mg Healthy Inhibited platelet cell signaling and thrombus
formation
[77]
Quercetin 730 mg/d Pre-hypertensive subjects




CVD cardiovascular disease, TNF-α tumor necrosis factor-α, TAC total antioxidant capacity
Fig. 1 Schematic representation in targeting different signaling and
metabolic pathways using quercetin as a novel therapeutic strategy in
cardiovascular disease prevention and treatment
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